Drug and alcohol addiction are treatable illnesses. They can be successfully managed and “arrested” such that they do not continue to harm a person’s life or compromise their health. Just as with any progressive illness, a patient should commit to a course of treatment that has been proven to eradicate their illness or reduce its impact. Heart disease, cancer, diabetes, morbid obesity, alzheimer’s – all of these have established medical treatments which can increase a person’s chance of survival and/or quality of life.
Addiction is both a physiological and behavioral illness. With opioid addiction in particular, there is a strong biological/physical basis as well as a highly significant psychological component. When both of these are adequately addressed, a patient has a new opportunity to recover.
For most individuals with a severe opioid addiction, is critically important to receive physical relief from the discomfort of opioid withdrawal symptoms. But this must also happen in conjunction with behavioral health counseling. Counseling addresses the emotional & psychological factors that contributed to the development of addiction in the first place, and counseling teaches the skills necessary to remain drug free over the long-term and to hopefully avoid future relapses.
Many people find that if they neglect one of these two key areas, then they are more vulnerable to relapse and rapid deterioration. When opioid detox is not a viable option for a particular patient, methadone and suboxone are clearly the medications of choice for addressing opioid withdrawal. Counseling provides the other half of the equation. All methadone programs across the country (as well as all suboxone-approved physicians) are required to insure that their patients are receiving some level of addiction counseling.
The essential ingredient is this mix is patient commitment. Having a genuine desire for a drug free life is as important as anything else. Becoming ready for change is a process in itself and varies from person to person. It is true that many people find their way into recovery because of a recent crisis in which things get so bad they hit a new low, or bottom. This does not have to happen though.
Sometimes hitting “bottom” brings with it dire consequences. If you have been contemplating making a change, please remember that it is not too late. There are many advantages to acting today as opposed to waiting another day. Addiction loves procrastination. Recovery begins now with your commitment to doing something about your problem!
Posted in Addiction Recovery, Addiction Treatment, Buprenorphine, Medication Assisted Treatment, Methadone, Methadone Clinics, Methadone Maintenance, Methadone Success, Methadone Treatment, Opiate Treatment, Recovery, Recovery Support, Suboxone, Suboxone Doctors
Tagged recovery process, relapse prevention
Acadia Healthcare is a leading behavioral healthcare services provider headquartered out of Franklin, Tennessee. The company was established in 2005 and has experienced rapid growth as a result of strategic acquisitions and a sharp focus on the delivery of psychiatric and chemical dependency treatment services.
Acadia recently bought out CRC Health Group for a reported $1.2 billion in a well-publicized sale which closed in February 2015. The acquisition significantly expanded Acadia’s opioid addiction treatment capabilities adding approximately 82 methadone/suboxone facilities nationwide. The company is nicely positioned to serve tens of thousands of patients on a daily basis who are struggling with opioid addiction and other associated illnesses. Methadone and buprenorphine products are utilized in association with a variety of counseling approaches.
Just added to Methadone.US are five of Acadia’s opioid treatment clinics located in San Diego, Riverside, Baltimore, Portland, and Southern Indiana.
Acadia’s mission statement:
Acadia Healthcare’s mission is to create behavioral health centers where people receive care that enables them to regain hope in a supportive, caring environment.
The company presently has behavioral healthcare facilities in 37 U.S. states, the United Kingdom, and Puerto Rico. These include residential treatment centers, inpatient psychiatric hospitals, outpatient clinics, and therapeutic school-based programs.
Posted in Addiction Treatment, Buprenorphine, Drug Rehab Programs, Methadone, Methadone Clinics, Methadone Maintenance, Methadone Programs, Methadone Success, Methadone Treatment, Opiate Addiction, Opiate Treatment, Suboxone, Suboxone Clinics, Suboxone Doctors
Tagged Acadia, CRC Health
Right Path is an opioid treatment provider operating in the greater Hampton Roads area of eastern Virginia. The organization specializes in the use of burprenorphine (the critical ingredient in Suboxone that alleviates opioid withdrawal symptoms).
Right Path currently have outpatient services in Virginia Beach, Newport News, and Suffolk, but plan to soon offer a location convenient for residents and visitors along the Outer Banks.
Recognizing the importance of individualized treatment plans, Right Path tailor their services to the needs of the individual patient. While suboxone is beneficial in eliminating the pain of opioid withdrawal, addiction counseling is essential in helping patients to understand the addiction and recovery process. Right Path provide addiction counseling as a component of their overall treatment program.
Evening and weekend hours are offered, and most insurance is accepted. The Right Path website has a helpful page that outlines various questions and issues that you might cover with your Suboxone Doctor in your first appointment. Their website provides another highly informative page on Suboxone which answers many common questions about this increasingly popular medication. More information on Right Path’s locations and contact information can be obtained here:
Posted in Addiction Recovery, Buprenorphine, Drug Treatment, Methadone, Opiate Addiction, Opiate Treatment, Relapse Prevention, Suboxone, Suboxone Clinics, Suboxone Doctors, Suboxone Physicians
Tagged opioid treatment, Right Path, suboxone therapy
Paul LePage, the governor of Maine, has announced that he is considering ceasing state-funded support for methadone. As an alternative, Maine is proposing that patients prescribed methadone be switched to a more affordable suboxone option as part of a $727,000 state budget cut. The story is here.
This is an indefensible decision with dire medical implications for opioid addicted patients currently receiving methadone. It equates to government officials making medical decisions that will negatively impact the health and well-being of thousands of people.
Representative Drew Gattine (a member of the Health & Human Services Committee) is quoted as saying the proposal shows a lack of understanding of the societal costs of addiction throughout the state of Maine.
Methadone and suboxone are both effective medications, but offer very unique characteristics and applications depending on the severity & chronicity of a patient’s opioid addiction. Buprenorphine (the actual opioid agonist contained in suboxone) has a much lower ceiling effect than does methadone meaning its effectiveness would be insufficient for a potentially large percentage of stable methadone patients on 60mg or more of methadone daily. Many patients on a moderate to high maintenance dose of methadone would not have their opioid withdrawal symptoms managed by even the maximum dosage allowed for suboxone – which is generally around 32 mg per day.
For a politician to, in essence, prescribe inappropriate medical treatment for a diagnosable medical condition is a huge state liability. The repercussions are alarming. Hopefully, the local medical establishment and other state officials will step in before irreversible damage is done. Methadone works. This cannot be denied.
Methadone has a long, proven track record of medical efficacy and cost effectiveness. Maine, in particular, has suffered in recent years with a severe opioid addiction epidemic. Reducing access to appropriate medical treatment like methadone will likely result in overdose deaths across Maine and an explosion of condemnation for the governor and his office.
Medication-assisted treatment (MAT) for opioid addiction is not a fad. It is scientifically proven effective and endorsed by multiple state & federal regulatory agencies as well as ASAM.
Posted in Addiction Treatment, Buprenorphine, Drug Treatment, Medication Assisted Treatment, Methadone, Methadone Clinics, Methadone Programs, Methadone Treatment, Opiate Treatment, Recovery, Suboxone, Suboxone Doctors
Tagged LePage, Main
Jana Burson is a North Carolina physician who specializes in the treatment of opioid addiction using medications like buprenorphine and methadone. Dr. Burson is a passionate caregiver and patient advocate with considerable experience in the field of addiction treatment. She maintains an informative blog on the topic of opioid addiction treatment and recently posted her comments and observations on a revealing 2012 study.
The 2012 study by Saxon et al is reported in her blog to have followed more than 700 patients over 24 weeks who were receiving either methadone or buprenorphine (the active ingredient in Suboxone). These patients were checked for specific red flag elevations that would suggest emerging liver damage or liver inflammation. None of the patients receiving methadone or buprenorphine had significant abberations in liver functioning. This led the researchers to conclude that neither medication causes liver damage.
A 2014 follow-up study by Soyka and others (published in the American Journal on Addictions) found the same results in their research of 181 patients on Suboxone (buprenorphine + naloxone).
Studies like these help to dispel misinformation around opioid treatment medications and their safety. Dr. Burson expressed that it was once routine to order liver function tests for patients on buprenorphine therapy, but that this is likely unnecessary given the more recent research validating methadone and buprenorphine’s safety in regard to liver functioning.
There are addiction-related illnesses, like Hepatitis C, that can have highly detrimental effects on the liver. According to Dr. Burson, the Soyka study also showed that buprenorphine was not harmful even in patients diagnosed with Hepatitis C.
Thorough research studies like these are important in further legitimizing the benefits & established safety profile of opioid treatment medications. Having access to safe medications helps hundreds of thousands of people find effective treatment for chronic opioid addiction.